Kenneth Spector, MD
Interventional Cardiology · Derby, CTNPI 1497818462
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,899 of the $2,299 with a category attached, or 82.6%. It is spread thinly across 22 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,180 and has fallen 81.7% since, to $217 in 2025. That places this record below the midpoint for interventional cardiology clinicians in CT, where the typical reported total is $5,446.
Across 102 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Welch Allyn$393
- Novartis$371
- Amgen$320
- E.r. Squibb & Sons, L.L.C.$256
- Johnson & Johnson$175
- Pfizer$112
- plus $673 from 16 others
What the payments were for
- Food & beverage$1,89983%
- Education$80%
- Other$39317%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Welch Allyn | 1 | $393 |
| Novartis | 17 | $371 |
| Amgen | 13 | $320 |
| E.r. Squibb & Sons, L.L.C. | 21 | $256 |
| Johnson & Johnson | 11 | $175 |
| Pfizer | 10 | $112 |
| Boston Scientific | 3 | $88 |
| Sanofi-aventis U.S. LLC | 4 | $78 |
| GE HealthCare | 2 | $73 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $62 |
| Lundbeck LLC | 3 | $56 |
| Heartflow, Inc. | 1 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| AstraZeneca | 3 | $48 |
| Medtronic | 1 | $27 |
| Merck | 1 | $24 |
| Philips North America LLC | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Preventice Services, LLC | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,299 in reported general payments places this provider in the 30th percentile of 73 interventional cardiology providers in Connecticut.
See all interventional cardiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 468 | $630,186 |
| XareltoRivaroxaban | 174 | $248,930 |
| EntrestoSacubitril/Valsartan | 34 | $47,097 |
| Repatha SureclickEvolocumab | 45 | $42,776 |
| Praluent PenAlirocumab | 33 | $34,567 |
| MultaqDronedarone Hcl | 21 | $32,632 |
| Rosuvastatin Calcium | 425 | $17,378 |
| Valsartan | 360 | $13,447 |
| Metoprolol Succinate | 431 | $10,337 |
| Atorvastatin Calcium | 443 | $6,364 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 14 | $4,900 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 150 | $4,894 |
| Losartan Potassium | 290 | $4,424 |
| Ezetimibe | 76 | $4,162 |
| Digoxin | 152 | $4,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $112 | $630,186468 claims |
| Johnson & JohnsonXarelto | $175 | $248,930174 claims |
| NovartisEntresto | $371 | $47,09734 claims |
| Sanofi-aventis U.S. LLCMultaq | $78 | $32,63221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 73 interventional cardiology providers in Connecticut.
Other interventional cardiology in Derby
- Osman JafferDerby$16K
- Amit VoraNew Haven$409K
- Craig ThompsonHartford$222K
- Michael NannaNew Haven$60K
- Jawad HaiderBloomfield$44K
- Sameer NagpalNew Haven$43K
- Khagendra DahalFarmington$42K
- Abdul QaziHartford$38K
- Sarfaraz MemonHartford$30K
- Edward CarrerasStratford$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.